Today, 69,744 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock are sold by Jean Jacques Bienaime

Today, 69,744 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock are sold by Jean Jacques Bienaime
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 69,744 shares of the company’s stock in a transaction that occurred on Monday, November 21st. The shares were sold at an average price of $87.56, for a total value of $6,106,784.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s): On Tuesday, November 22nd, Jean Jacques Bienaime sold 69,743 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $85.69, for a total value of $5,976,277.67. On Monday, November 7th, Jean Jacques Bienaime sold 70,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $82.52, for a total value of $5,776,400.00. On Tuesday, November 8th, Jean Jacques Bienaime sold 140,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $82.67, for a total value of $11,573,800.00. On Friday, October 28th, Jean Jacques Bienaime sold 120,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $81.30, for a total value of $9,756,000.00. On Monday, October 17th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $84.39, for a total value of $3,516,193.74. On Friday, October 14th, Jean Jacques Bienaime sold 64,125 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $86.96, for a total value of $5,576,310.00. On Thursday, September 29th, Jean Jacques Bienaime sold 53,125 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $93.65, for a total value of $4,975,156.25. On Friday, September 16th, Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $95.34, for a total value of $13,096,665.12.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 88.10 on Friday. The firm’s market capitalization is $15.15 billion. BioMarin Pharmaceutical Inc. has a 52-week low of $62.12 and a 52-week high of $107.56. The stock’s 50 day moving average price is $86.66 and its 200-day moving average price is $89.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, October 27th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.13. The firm earned $279.90 million during the quarter, compared to the consensus estimate of $289.70 million. BioMarin Pharmaceutical had a negative net margin of 46.22% and a negative return on equity of 8.54%. The company’s revenue was up 34.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. Equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post ($3.73) EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of BMRN. Cornerstone Advisors Inc. increased its position in BioMarin Pharmaceutical by 22.0% in the third quarter. Cornerstone Advisors Inc. now owns 1,159 shares of the company’s stock valued at $107,000 after buying an additional 209 shares in the last quarter. Rockefeller Financial Services Inc. bought a new position in BioMarin Pharmaceutical during the second quarter valued at about $111,000. Independent Portfolio Consultants Inc. bought a new position in BioMarin Pharmaceutical during the third quarter valued at about $121,000. Toronto Dominion Bank increased its position in BioMarin Pharmaceutical by 57.8% in the third quarter. Toronto Dominion Bank now owns 1,401 shares of the company’s stock valued at $130,000 after buying an additional 513 shares in the last quarter. Finally, Meeder Asset Management Inc. bought a new position in BioMarin Pharmaceutical during the second quarter valued at about $140,000. Hedge funds and other institutional investors own 93.68% of the company’s stock.

BMRN has been the topic of several research analyst reports. Vetr raised BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating and set a $111.64 price objective on the stock in a research note on Wednesday, August 24th. Wedbush reissued a “neutral” rating and issued a $108.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, July 28th. Jefferies Group reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, August 17th. Zacks Investment Research raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $111.00 price objective on the stock in a research note on Tuesday, August 9th. Finally, Cowen and Company set a $150.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, September 8th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $115.24.

About BioMarin Pharmaceutical

Related posts

Leave a Comment